Services

Home Services

Better understand drug
responses by assaying
more targets.

Contact us to discuss tracking drug safety or efficacy signals in your preclinical or clinical trials.

20,000

genes profiled, multiple species, history of delivery to thousands of patients

20,000

genes profiled, multiple species, history of delivery to thousands of patients

Services

Get Insights Into Drug Responses

Advanced organ damage biomarkers based on reliable machine learning methods. Get a quicker and more accurate picture of drug reactions in your patients. Reach out and we can discuss providing these tools to your team.

On-demand bioinformatics deep-dives: need to better understand adverse events or troubleshoot genomic assay performance? We are an attentive partner. Follow the contact link to discuss how we can help in a hurry.

Biomarker development for efficacy pathways of interest. Contact us to discuss how our platform can provide clarity to complex biology.

Genomic patient selection tools to find the populations that will benefit most. Get in touch to discuss details of the population and indication.

Testimonials

What our partners say about the impact of our diagnostic services.

Drug-induced liver injury (DILI) is a common finding in preclinical and clinical studies. The FDA scrutinizes data for any sign of DILI. False positive signals from AST/ALT can trigger significant program delays to investigate mechanism of action and confirm drug safety. I want a liver toxicity test with higher sensitivity and specificity.

Jay Stallons PhD DBAT

It’s hard to separate true drug safety signals from false ones with current tests. This harms clinical safety trial power. Liver toxicity screening is stuck in the ‘90s with very low data input. The current LFT is insufficent.

Julia Warren MD PhD

MPathy Bio’s focus on reduced false positives in toxicity biomarkers is well aligned with the needs of our cohort studies on the extension of health and lifespan in dogs. Having high sensitivity and specificity tests for therapy-induced liver toxicity would be superior to the relatively simplistic status quo that can be inaccurate due to a transient or benign biological state in the dog, such as dehydration.

Daniel Promislow, head of the Dog Aging Project

Why Choose Us

We have a track record of delivering next level molecular insights to improve patient care.

Experience

We have developed genomic diagnostic products serving hundreds of thousands of patients worldwide.

Responsive Analysis Team

We are a nimble team and can jump on your urgent omic analysis needs.

Customized Assays And Analytics

Contact us to talk through your team's specific scientific needs.

Copyright 2024 @ All Right reserved.